TRIAL WITH BACILLUS-CALMETTE-GUERIN AND EPIRUBICIN COMBINATION IN THE PROPHYLAXIS OF SUPERFICIAL BLADDER-CANCER

被引：15

作者：

EROL, A

OZGUR, S

BASAR, M

CETIN, S

机构：

[1] Department of Urology, Advanced Specialization Hospital of Turkey, Ankara

来源：

UROLOGIA INTERNATIONALIS | 1994年 / 52卷 / 02期

关键词：

SUPERFICIAL BLADDER CANCER; IMMUNOTHERAPY; INTRAVESICAL THERAPY; BACILLUS CALMETTE-GUERIN; EPIRUBICIN;

D O I：

10.1159/000282576

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The efficacy and side effects of the prophylactic intravesical bacillus Calmette-Guerin and epirubicin combination therapy were evaluated in 14 patients who underwent transurethral resection for Ta-T1 superficial bladder cancer. Therapy was started 7-10 days after the operation and maintained weekly for 6 weeks and then monthly for 6 months unless withdrawal due to side effects. Instillation of 50 mg epirubicin (Farmorubicin, Farmitalia Carlo Erba) diluted in 50 ml saline was followed by 80 mg of the Connaught strain bacillus Calmette-Guerin (ImmuCyst, Pasteur Merieux) in 50 ml saline and the duration of instillation was 2 h for each drug. All the patients experienced moderate to severe cystitis and fever. Side effects necessitated discontinuation of the therapy in 5 patients (35.7%). Therapy was delayed in 7 patients (50%) for reasons related or unrelated to the side effects. Of the 9 patients who completed the course, 8 (89%) had no tumor recurrence 10-16 months (mean 14 months) after therapy. Results obtained revealed that this treatment schedule cannot be tolerated by a considerable number of the patients. Mainly the side effects of the combination are emphasized in this report. The therapeutic efficacy of such a combination has yet to be determined and further clinical studies are warranted.

引用

页码：69 / 72

页数：4

共 12 条

[1]

Lamm D.L., Van Der Meijden A., Morales A.D.P.M., Et al., Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer, J Urol, 147, pp. 596-600, (1992)

[2]

Mori K., Lamm D.L., Crawford E.D., A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: A South-West Oncology Group Study, Urol Int, 41, pp. 254-259, (1986)

[3]

Brosman S.A., Lamm D.L., The preparations handling and use of intravesical bacillus Cal- mettc-Guérin for the management of stage Ta, Tl, carcinoma in situ and transitional cell cancer, J Urol, 144, pp. 313-315, (1990)

[4]

Kavoussi L.R., Brown E.J., Ritchey J.K., Et al., Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response, J Clin Invest, 85, pp. 62-67, (1990)

[5]

Ratliff T.L., Bacillus Calmette-Guérin (BCG): Mechanism of action in superficial bladder cancer, Urology, 37, pp. 8-12, (1991)

[6]

Sarosdy M.F., Principles of intravesical chemotherapy and immunotherapy, Urol Clin North Am, 19, pp. 509-519, (1992)

[7]

Martinez-Pineiro J.A., Leon J.J., Martinez-Pinei- Ro L., Et al., Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer, J Urol, 143, pp. 502-506, (1990)

[8]

Kurth K., Vd Vijgh W.J.F., Ten Kate F., Et al., Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder, J 12 Urol, 146, pp. 1508-1513, (1991)

[9]

Melekos M.D., Pantazakos A., Markou S., Et al., Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer, Int Urol Nephrol, 22, pp. 433-440, (1990)

[10]

Matsumura Y., Tsushima T., Ozaki Y., Et al., Intravesical chemotherapy with 4’-epi-adria- mycin in patients with superficial bladder tumors, Cancer Chemother Pharmacol, 16, pp. 176-177, (1986)

← 1 2 →